Clinical and Sociodemographic Characteristics of Patients With Relapsed and/or Refractory Multiple Myeloma and Their influence on Treatment in the Real-World Setting in Spain: The CharisMMa Study

Autor: Maialen Sirvent, Alonso Fernandez, Carmen Montes-Gaisán, Gabriela Bustamante, Rafael Rios, Sebastián Garzón, Yolanda González, Laura Rosiñol, Marta Grande, Ernesto Pérez, Esther G. González, Jose M Arguiñano, Dunia de Miguel, Andrea Naves, Enrique M. Ocio

Publikováno v: Clin Lymphoma Myeloma Leuk . 2022 Apr;22(4):e241-e249
UCrea Repositorio Abierto de la Universidad de Cantabria
Universidad de Cantabria (UC)
Dipòsit Digital de la UB
Universidad de Barcelona

The characteristics of patients with RRMM in the real-world setting often differ from those enrolled in clinical trials, challenging therapeutic decisions in day-to-day practice. We retrospectively analyzed the sociodemographic and clinical character

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cff2236a7fe88041e7064b24b9b7ce14
http://hdl.handle.net/10902/24497

Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial

Autor: María Cortés-Rodríguez, Norma C. Gutiérrez, Juan J. Lahuerta, María del Carmen Couto, Enrique M. Ocio, Jose M Arguiñano, Jesús F. San-Miguel, María José Casanova, Jesús Martín, M. Teresa Cedena, Javier de la Rubia, Maria Luisa Martin, Ana Isabel Teruel, Esther González, Bruno Paiva, Ernesto Pérez-Persona, Verónica González-Calle, Laura Rosiñol, María José Calasanz, Cristina Encinas, Rafael Rios, Morton Coleman, Ruben Niesvizky, Miguel T. Hernandez, Ana M. Vale, Maria-Victoria Mateos, Adrian Alegre, Mercedes Gironella, Noemi Puig, Sebastián Garzón, Ricarda García-Sánchez, Felipe de Arriba, Guillermo Martín-Sánchez, Joan Bladé, Mario Arnao, Marta González, Fernando Escalante, Albert Oriol

Publikováno v: Blood Cancer J . 2021 May 21;11(5):101
UCrea Repositorio Abierto de la Universidad de Cantabria
Universidad de Cantabria (UC)
Blood Cancer Journal
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Blood Cancer Journal, Vol 11, Iss 5, Pp 1-11 (2021)
BLOOD CANCER JOURNAL
r-FISABIO. Repositorio Institucional de Producción Científica
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Digital.CSIC. Repositorio Institucional del CSIC
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
Scientia

© The Author(s) 2021.
Although case-control analyses have suggested an additive value with the association of clarithromycin to continuous lenalidomide and dexamethasone (Rd), there are not phase III trials confirming these results. In this pha

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d92cad2ad8e0b5e923b8ea47e9c9005f
http://hdl.handle.net/10902/23826

Single-Agent Ibrutinib As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL) in Routine Clinical Practice in Spain

Autor: Jose M Arguiñano, Angeles Medina, Ana Lario, Santiago Osorio-Prendes, Javier Loscertales, Lucrecia Yáñez, Patricia Baltasar, Fernando De Marco, Julio Delgado, Margarita Fernández de la Mata, Macarena Ortiz Pareja, Miguel Ganuza Fernandez, Inmaculada Pérez, Alicia Rodríguez, Rafael Ramos, Ana Cristina Godoy, Ruben Fernandez, Alexia Suárez Cabrera, Jose Luis Bello, Jose Angel Hernandez-Rivas, Carmen Losada, Montserrat López Rubio, Aima Lancharro Anchel, María-Jesús Vidal, Eduardo Rios Herranz, Angel Ramirez Payer, Isidro Jarque, Ana Célia Carneiro Oliveira, Maria José Berruezo, Pau Abrisqueta Costa, Carolina Cuellar, Paloma Martin, María-Dolores García-Malo, Ernesto Pérez Persona, María José Terol, Cristina Loriente, Alicia Smucler Simonovich, Ricardo Francisco Garcia, Miguel Villanueva

Publikováno v: Blood. 136:32-33

Introduction. Ibrutinib is a first-in-class, oral, once-a-day Bruton's tyrosine kinase inhibitor that achieves high overall response rates and durable remissions in patients with chronic lymphocytic leukemia (CLL) including those with high-risk featu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d76bf26c288ba86c1684e5da66b1577d
https://doi.org/10.1182/blood-2020-136036